Once thought of as ‘undruggable’ due to the lack of classic drug-binding sites, the recent approval of KRAS G12C inhibitors sotorasib and adagrasib in locally advanced or metastatic NSCLC has set a new paradigm for the treatment of KRAS G12C-mutated cancers. This evidence concerns the gene KRAS and cancer.